Nautilus Biotechnolgy, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NAUT research report →
Range $3.5 – $3.5
Price Chart
About the company
Nautilus Biotechnology, Inc. , a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
- CEO
- Sujal Patel
- IPO
- 2020
- Employees
- 128
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on NAUT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $270.03M
- P/E
- -5.28
- PEG
- -0.65
- P/S
- 729.99
- P/B
- 2.65
- EV/EBITDA
- -6.01
- Div Yield
- 0.00%
- Gross Margin
- -362.50%
- Op Margin
- -15105.66%
- Net Margin
- -13816.75%
- ROE
- -42.68%
- ROIC
- -44.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-6,465,000-1.8%
- Op Income
- $-66,837,000
- Net Income
- $-59,001,000+16.6%
- EPS
- $-0.47+16.1%
- OCF Growth
- +14.3%
- FCF Growth
- +15.2%
- 52W High
- $4.31
- 52W Low
- $0.84
- 50D MA
- $1.97
- 200D MA
- $2.13
- Beta
- 0.87
- RSI (14)
- 46
- Avg Volume
- 6.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Nautilus said Q3 was early-commercial but showed strong assay execution, with proteoform demand building ahead of a 2027 Voyager launch.· October 27, 2026
- Q3 revenue was $200,000, driven by MJFF grant revenue and Early Access service revenue.
- Net loss was $15.6 million, or $0.12 per share, versus $13.6 million, or $0.11 per share a year ago.
- Cash, cash equivalents and investments ended the quarter at $114.3 million, with cash use of $14.9 million in Q3 and runway into Q1 2028.
- Management said Q4 revenue should rise sequentially from Q3, excluding SEEDS, and full-year 2026 revenue should exceed the prior outlook of about $500,000.
- The company reiterated its goal of 20 proteoform assays by mid-2028 and said Voyager commercialization remains on track for pre-orders in early 2027 and shipments in mid-2027.
Total revenue for the third quarter was $200,000, consisting of grant revenue from the Michael J. Fox Foundation-funded alpha-synuclein proteoform assay development and service revenue from the Early Access Program. Net loss was $15.6 million, or $0.12 per share, compared with a net loss of $13.6 million, or $0.11 per share, in the prior-year period. Total operating expenses were $16.9 million, up approximately 10% from $15.5 million a year ago; R&D was $10.2 million, up approximately 6% from $9.6 million; and SG&A was $6.8 million, up approximately 15% from $5.9 million. Cash, cash equivalents and investments were $114.3 million at quarter-end versus $129.2 million at the end of Q2, reflecting cash use of approximately $14.9 million. For Q4, management expects revenue to again come primarily from grant funding and Early Access services, with revenue growing sequentially from Q3 excluding any contribution from ARPA-H SEEDS work. Full-year 2026 revenue is now expected to exceed the prior outlook of approximately $500,000.
Sujal Patel framed the quarter around a strategic shift toward proteoforms, arguing that making functional biology measurable is Nautilus’s core opportunity. He emphasized that the company’s Iterative Mapping technology can capture single-molecule proteoform detail that current proteomics methods miss, and said customer pull is increasing as the field focuses more on proteoforms. His tone was confident and long-term oriented, highlighting Nature Methods validation, early customer traction, ARPA-H SEEDS, and the plan to expand to 20 assays by mid-2028.
Anna Mowry described Nautilus as still in an early commercial phase, with revenue coming from grant funding and Early Access services and the broader Voyager launch still ahead. She cited Q3 revenue of $200,000, operating expenses of $16.9 million, and a net loss of $15.6 million, then said full-year operating expense growth should remain in the single digits. She also said the company ended with $114.3 million in cash, cash equivalents and investments, used about $14.9 million in the quarter, and believes runway extends into Q1 2028. She added that Nautilus is considering a capital raise between now and mid-2027 to fund assay expansion, platform capability, and commercial team growth.
Analysts focused on SEEDS funding mechanics, AI/data commercialization, early-access pipeline momentum, launch milestones, capital spending, and how the company will build demand for Voyager. Management said SEEDS revenue will be recognized over the four-year program as work is completed, and Sujal described the AI opportunity as real but still early because current proteomics datasets lack the reproducibility needed for frontier models. On commercialization, management said the current pipeline is still mostly tau-related but AKT1 activity is starting, with the sales team small but expected to expand in 2027; they also said launch depends on shipping and operationalizing a beta unit this year, then being ready for pre-orders in early 2027 and shipments in mid-2027. On CapEx, Anna said there are no material facility or equipment investments planned beyond targeted spending, and on launch demand Sujal said the company will need to build the instrument funnel in academic, nonprofit and pharma channels, with grant funding for instruments becoming more dependent on 2028 cycles.
The bullish case from this call is that Nautilus is showing reproducible assay performance while moving multiple programs forward at once. Management pointed to strong median CVs for AKT1, EGFR and P53, rising customer interest, and external validation from Nature Methods, MJFF and ARPA-H. The company also expects sequential Q4 revenue growth, a 2027 commercial launch path, and a growing assay menu that could support future instrument demand.
The main risks are that Nautilus is still generating very little revenue and remains in an early-commercial, loss-making phase. Management acknowledged the launch path depends on a beta unit this year, instrument shipment execution, and continued assay development, while 2027 demand may rely heavily on grants and pharma/philanthropy because S10 funding is less certain. The company also said the commercial team is still small and that meaningful instrument pull-through will take time to build.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 44.0%
- Shares Outstanding
- 127.37M
- Float Shares
- 56.04M
of shares held by institutions
95 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Perceptive Advisors LLC | 11.63M | ▼ 960.00K |
| A16z Capital Management, L.L.C. | 9.06M | ▼ 8.59M |
| Cercano Management LLC | 7.17M | 0 |
| Madrona Venture Group, LLC | 6.02M | 0 |
| Blackrock, Inc. | 3.13M | ▲ 439.29K |
| Vanguard Group Inc | 2.60M | ▲ 166.39K |
| Vanguard Capital Management LLC | 2.55M | 0 |
| Comprehensive Financial Management LLC | 2.21M | 0 |
| Acadian Asset Management LLC | 2.13M | ▲ 1.08M |
| Citadel Advisors LLC | 1.90M | ▲ 1.90M |
| Renaissance Technologies LLC | 1.62M | ▲ 927.57K |
| Geode Capital Management, LLC | 1.40M | ▲ 138.85K |
Held by 95 ETFs
Biggest fund positions in NAUT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Posard Matthew L. | other | 45,000 |
| Jun 18, 26 | NAZEM FARZAD | other | 45,000 |
| Jun 18, 26 | Akinsanya Karen | other | 45,000 |
| Jun 18, 26 | McIlwain Matthew S | other | 45,000 |
| Jun 18, 26 | Epperly Melissa B, | other | 45,000 |
| Jun 2, 26 | AH Equity Partners Bio II, L.L.C. | sell | 4,615,974 |
| Jun 2, 26 | AH Equity Partners Bio II, L.L.C. | sell | 384,026 |
| Mar 4, 26 | Patel Sujal M | buy | 25,000 |
| Mar 2, 26 | Mowry Anna | other | 160,000 |
| Mar 2, 26 | Mallick Parag | other | 280,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NAUT coverage
Recent articles, reports, and earnings notes.
No research on NAUT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NAUT report →Nautilus: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 5
Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
seekingalpha.com · Oct 28
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 27
Nautilus Biotechnology Q3 Earnings Call Highlights
marketbeat.com · Oct 27
Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium
globenewswire.com · Oct 27
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
globenewswire.com · Oct 27
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
globenewswire.com · Oct 15
Nautilus Biotechnology Sees Unusually High Options Volume (NASDAQ:NAUT)
defenseworld.net · Oct 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.